Company intelligence / Profile preview

CrystalBioSciences

Emeryville, California, United Statessec.gov ↗

Ownership: Private
Development stage: Other

Overview

Crystal Bioscience developed a unique chicken-based human therapeutic antibody discovery engine, enabling the generation of antibodies against difficult targets such as GPCRs and ion channels. Its technology has been used in immuno-oncology and pain indications. The company was acquired by Ligand Pharmaceuticals in 2017 for $25 million plus milestones, and its platform is now part of Ligand’s OmniAb suite.

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodyBispecific monoclonal antibody (via platform capabilities)
Industry: Biotech

Partnerships

Boehringer IngelheimAlexo TherapeuticsAchaogenUndisclosed large pharmaceutical company

Beyond the preview

Go deeper on CrystalBioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CrystalBioSciences.

Explore the full profile